New diagnostic and prognostic markers are required to aid in the early detection of cancer and for the monitoring of the efficacy of a treatment. Creative Biolabs, a world-leading service provider, is now proud to introduce our in vitro diagnostic (IVD) antibody & immunoassay development services to global clients. Our services can be customized towards a wide range of disease biomarkers, such as tissue polypeptide antigen (TPA).
TPA was first described as a heterogeneous combination of glycoprotein molecules of molecular weight between 20-45 kDa with a cytokeratin-like structure. Moreover, TPA appears to be related to type II cytokeratins in that there is a significant sequence identity between a major fragment of TPA and cytokeratin 8 and extensive homology with cytokeratin 18. Immunologically, TPA is defined as a combination of non-epidermal cytokines 8, 18, and 19. This protein is produced during the S and G2 phase of the cell cycle and released into the circulation during mitosis. The TPA release is a normal characteristic of cell proliferation. The TPA levels in serum are increased in infection and tissue repair. Many studies have implicated that the increased serum levels of TPA reflect the proliferative activity of cancer cells and are considered as a significant tumor marker.
The serum TPA levels are significantly increased in various cancers such as lung, gastrointestinal, bladder, and breast cancer. For instance, a study shows that the serum level of TPA and IL-6 is different between localized and metastatic breast cancer. They both have a good predictive value for response to chemotherapy of breast cancer. The combination test of these two tumor markers increases the sensitivity for detecting breast cancer up to 96.7%. Besides, a study reported the combination of carcinoembryonic antigen (CEA), with tissue polypeptide-specific antigen (TPS) or TPA, can significantly increase the quality of detection of distant metastases.
Detection of the level of biomarkers in different biological samples can often be achieved by rapid and sensitive antibody-based methods. At Creative Biolabs, we offer custom-tailored IVD antibody and immunoassay development services targeting various disease biomarkers, such as TPA. We know the importance of the development of high-quality antibodies to produce reliable kits. With years of experience, we offer services covering the whole process of kit development. For more detailed information about what we offer for each stage of the development process, please click the links below:
Please feel free to contact us for more information and discuss your project needs.
References
For Research Use Only.
